We are live on
!
Find out more
VanEck Associates Portfolio holdings
AUM
$133B
1-Year Est. Return
72.99%
This Fund
S&P 500
This Quarter
Est. Return
+4.01%
1 Year Est. Return
+72.99%
3 Year Est. Return
+157.94%
5 Year Est. Return
+206.35%
10 Year Est. Return
+770.56%
AUM
$21.4B
AUM Growth
+$1.27B
(+6.3%)
Cap. Flow
+$730M
Cap. Flow
% of AUM
3.41%
Top 10 Holdings %
Top 10 Hldgs %
26.79%
Holding
881
New
137
Increased
443
Reduced
202
Closed
30
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
AngloGold Ashanti
AU
|
+$259M |
| 2 |
Vale
VALE
|
+$83M |
| 3 |
WPX
WPX Energy, Inc.
WPX
|
+$44.4M |
| 4 |
Gold Fields
GFI
|
+$39.7M |
| 5 |
Royal Gold
RGLD
|
+$35.7M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
MON
Monsanto Co
MON
|
+$109M |
| 2 |
Newmont
NEM
|
+$96M |
| 3 |
B
Barrick Mining
B
|
+$77.1M |
| 4 |
Franco-Nevada
FNV
|
+$63.2M |
| 5 |
GG
Goldcorp Inc
GG
|
+$58M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Materials | 50.75% |
| 2 | Energy | 16.94% |
| 3 | Healthcare | 6.45% |
| 4 | Technology | 5.96% |
| 5 | Consumer Staples | 2.71% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
201
Perrigo
PRGO
$1.4B
| $15.2M | 0.07% |
208,790
+34,794
| +20% | +$2.68M |
|
|
KLDX
202
DELISTED
KLONDEX MINES LTD
KLDX
| $15.1M | 0.07% |
6,532,653
-2,204,523
| -25% | -$5.37M |
|
203
Home Depot
HD
$332B
| $14.7M | 0.07% |
75,355
+32,738
| +77% | +$6.12M |
|
204
Sanofi
SNY
$104B
| $14.5M | 0.07% |
361,195
+47,420
| +15% | +$1.87M |
|
205
Prospect Capital
PSEC
$1.06B
| $14.4M | 0.07% |
2,149,984
+97,381
| +5% | +$647K |
|
206
Teva Pharmaceuticals
TEVA
$35.9B
| $14.3M | 0.07% |
587,244
-14,369
| -2% | -$293K |
|
207
Toro Company
TTC
$8.93B
| $14.2M | 0.07% |
236,017
+7,072
| +3% | +$426K |
|
208
Novartis
NVS
$295B
| $14M | 0.07% |
207,201
+36,459
| +21% | +$2.52M |
|
209
GSK
GSK
$103B
| $13.8M | 0.06% |
274,743
+5,937
| +2% | +$299K |
|
|
NVO
210
Novo Nordisk
NVO
$216B
| $13.7M | 0.06% |
596,108
+101,554
| +21% | +$2.41M |
|
|
CCT
211
DELISTED
Corporate Capital Trust, Inc.
CCT
| $13.7M | 0.06% |
876,677
+27,506
| +3% | +$457K |
|
212
AstraZeneca
AZN
$263B
| $13.4M | 0.06% |
190,711
+5,015
| +3% | +$361K |
|
|
DCUD
213
DELISTED
Dominion Energy, Inc 2016 Series A Corporate Units
DCUD
| $13.3M | 0.06% |
287,255
+15,718
| +6% | +$703K |
|
|
SUPV
214
Grupo Supervielle
SUPV
$833M
| $13.2M | 0.06% |
1,243,886
+146,000
| +13% | +$3.18M |
|
215
FS KKR Capital
FSK
$2.98B
| $12.4M | 0.06% |
421,984
+32,169
| +8% | +$981K |
|
|
GRFS
216
Grifois
GRFS
$5.16B
| $12.4M | 0.06% |
576,179
+77,105
| +15% | +$1.68M |
|
217
Ternium
TX
$9.29B
| $12.4M | 0.06% |
355,519
-94,916
| -21% | -$3.55M |
|
218
Jazz Pharmaceuticals
JAZZ
$15.9B
| $12.4M | 0.06% |
71,695
-5,858
| -8% | -$958K |
|
|
GAU
219
Galiano Gold
GAU
$486M
| $12.2M | 0.06% |
11,414,103
+475,728
| +4% | +$536K |
|
220
Neurocrine Biosciences
NBIX
$17.7B
| $12.1M | 0.06% |
123,542
+19,302
| +19% | +$1.73M |
|
221
AGNC Investment
AGNC
$12.3B
| $12M | 0.06% |
646,451
+69,900
| +12% | +$1.32M |
|
222
Occidental Petroleum
OXY
$57B
| $11.5M | 0.05% |
138,013
+38,399
| +39% | +$3.07M |
|
223
Bausch Health
BHC
$1.65B
| $11.5M | 0.05% |
494,586
-228,537
| -32% | -$4.73M |
|
224
Viatris
VTRS
$20.1B
| $11.4M | 0.05% |
315,905
+45,277
| +17% | +$1.78M |
|
|
KMI.PRA
225
DELISTED
Kinder Morgan, Inc.
KMI.PRA
| $11.4M | 0.05% |
328,289
+17,961
| +6% | +$578K |
|
Similar funds
DAM
VanEck Associates's Q2 2018 Portfolio in Review
As of Q2 2018, VanEck Associates held 881 positions worth $21.4B, up 6.3% from $20.1B the previous quarter. Its ten largest holdings account for 27% of the portfolio.
VanEck Associates deployed $730M of net new capital in Q2 2018, opening 137 new positions and adding to 443 existing holdings. Its largest new stake was Colgate-Palmolive: 345,613 shares worth $22.4M.
By sector, the portfolio is most concentrated in Materials at 51% of assets, down from 52% a quarter earlier, followed by Energy and Healthcare.
On the sell side, the largest reduction was Newmont, an estimated $96M trimmed.
- VanEck Associates's largest Q2 2018 buy was Colgate-Palmolive: 345,613 shares worth $22.4M.
- VanEck Associates added most to AngloGold Ashanti in Q2 2018, an estimated $259M increase.
- VanEck Associates's biggest Q2 2018 reduction was Newmont, cutting an estimated $96M.
- VanEck Associates fully exited Monsanto Co in Q2 2018, selling an estimated $109M.
- VanEck Associates's ten largest holdings make up 27% of its $21.4B portfolio in Q2 2018.
- VanEck Associates opened 137 new positions and closed 30 in Q2 2018.
- VanEck Associates's portfolio value rose 6.3% quarter-over-quarter to $21.4B.
Based on VanEck Associates's 13F filing for Q2 2018, filed 13 Aug 2018.